Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052) by Fogel, Jessica M. et al.
B R I E F R E P O R T
Undisclosed Antiretroviral Drug
Use in a Multinational Clinical Trial
(HIV Prevention Trials Network 052)
Jessica M. Fogel,1 Lei Wang,3 Teresa L. Parsons,2 San-San Ou,3
Estelle Piwowar-Manning,1 Ying Chen,3 Victor O. Mudhune,8
Mina C. Hosseinipour,9 Johnstone Kumwenda,10 James G. Hakim,11
Suwat Chariyalertsak,12 Ravindre Panchia,13 Ian Sanne,14
Nagalingeswaran Kumarasamy,15 Beatriz Grinsztejn,16 Joseph Makhema,19
Jose Pilotto,17 Breno R. Santos,18 Kenneth H. Mayer,4 Marybeth McCauley,5
Theresa Gamble,6 Namandjé N. Bumpus,2 Craig W. Hendrix,2
Myron S. Cohen,7 and Susan H. Eshleman1
1Department of Pathology, and 2Department of Medicine, Johns Hopkins University
School of Medicine, Baltimore, Maryland; 3Vaccine and Infectious Disease Division,
Fred Hutchinson Cancer Research Center, Seattle, Washington; 4Fenway Health,
Boston, Massachusetts; 5FHI360, Washington, District of Columbia; 6FHI360,
Durham, North Carolina; 7Department of Medicine, University of North Carolina,
Chapel Hill; 8KEMRI-CDC HIV Research Branch, Kisumu, Kenya; 9UNC Project,
Kamuzu Central Hospital, Lilongwe, and 10College of Medicine, Blantyre, Malawi;
11Department of Medicine, University of Zimbabwe, Harare; 12Research Institute for
Health Sciences, Chiang Mai University, Thailand; 13Perinatal HIV Research Unit,
and 14Clinical HIV Research Unit, Department of Medicine, Faculty of Health
Sciences, University of the Witwatersrand, Johannesburg, South Africa;
15Y. R. Gaitonade Center for AIDS Research and Education, Chennai, India;
16Laboratorio de Pesquisa Clinica em DST/AIDS, Instituto de Pesquisa
Clinica Evandro Chagas-Fiocruz, and 17Hospital Geral de Nova Iguacu and
Laboratorio de AIDS e Imunologia Molecular-IOC/Fiocruz, Rio de Janeiro, and
18Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil; and 19Botswana–
Harvard School of Public Health AIDS Initiative Partnership, Gaborone
The HIV Prevention Trials Network 052 study enrolled serodis-
cordant couples. Index participants infected with human im-
munodeficiency virus reported no prior antiretroviral (ARV)
treatment at enrollment. ARV drug testing was performed ret-
rospectively using enrollment samples from a subset of index
participants. ARV drugs were detected in 45 of 96 participants
(46.9%) with an undetectable viral load, 2 of 48 (4.2%) with
a low viral load, and 1 of 65 (1.5%) with a high viral load
(P < .0001); they were also detected in follow-up samples from
participants who were not receiving study-administered treat-
ment. ARV drug testing may be useful in addition to self-
report of ARV drug use in some clinical trial settings.
Keywords. HIV; antiretroviral drug; self-report; HPTN 052;
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Many human immunodeficiency virus (HIV) treatment and
prevention trials enroll HIV-infected participants who report
no history of antiretroviral (ARV) drug use. This information is
often obtained by self-report. Undisclosed “off-study” ARV use
before enrollment or during a clinical trial may confound study
outcomes. The Partners in Prevention HSV/HIV Transmission
study observed undisclosed ARV use in 46% of HIV-infected
participants who were virally suppressed at enrollment and re-
ported no prior ARV treatment (ART) [1, 2].
The HIV Prevention Trials Network (HPTN) 052 study en-
rolled 1763 HIV-serodiscordant couples in Africa, Asia, and the
Americas (2005–2010) [3]. Eligibility criteria for HIV-infected
index participants included a CD4 cell count of 350–550 cells/mm3
and no prior ART; prior receipt of a short-term ARV regimen
for prevention ofmother-to-child transmission ofHIV (pMTCT)
was allowed [3]. Index participants were randomized in an un-
blinded fashion to initiate ART immediately after enrollment
irrespective of their CD4 cell count (early ART arm) or to initi-
ate ART once their CD4 cell count reached ≤250 cell/mm3
at 2 consecutive measurements (delayed ART arm), or if an
AIDS-defining illness developed. Early initiation of ART in
HIV-infected index participants was shown to reduce HIV
transmission to HIV-uninfected partners by 96% [3].
During an interim review of HPTN 052 by the Study Moni-
toring Committee, it was noted that some HIV-infected partici-
pants were virally suppressed at the time of study enrollment.
This finding raised concerns that some participants may have
been receiving ART at enrollment and that some participants
in the delayed ART arm may have continued off-study ARV
use after enrollment. Here, we describe a post hoc analysis of
unreported ARV drug use in the HPTN 052 trial.
METHODS
Samples Used for Analysis
Enrollment plasma samples from index participants were tested,
including (1) all available samples from participants with viral
loads ≤400 copies/mL (virally suppressed group), (2) all available
samples from participants with viral loads of 401–1000 copies/mL
(low viral load group), and (3) samples from a randomly select-
ed subset of participants with viral loads >1000 copies/mL
(high viral load group, stratified by site). Follow-up samples
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from a subset of participants were also analyzed. Results from
ARV testing were not returned to study sites or study partici-
pants. One study site (Pune, India) did not provide approval
for ARV testing and was not included in this substudy.
Laboratory Methods
HIV loads and CD4 cell counts were determined in the HPTN
052 trial [3]. The ARV drugs were measured using liquid chro-
matography–tandem mass spectrometry (API 4000 triple
quadrupole mass analyzer; AB SCIEX). This testing was per-
formed at the Clinical Pharmacology Analytical Laboratory
( Johns Hopkins University School of Medicine) using assays
validated according to the US Food and Drug Administration
bioanalytical guidelines. Samples were screened for 16 ARV
drugs, including protease inhibitors (amprenavir, atazanavir,
darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir,
and tipranavir), nucleoside/nucleotide reverse-transcriptase
inhibitors (emtricitabine [FTC], lamivudine [3TC], stavudine
[d4T], tenofovir [TFV], and zidovudine [ZDV]), and nonnu-
cleoside reverse-transcriptase inhibitors (efavirenz and nevira-
pine [NVP]). Analytes were extracted from 50 µL of plasma by
protein precipitation with methanol and were separated with
reversed-phase liquid chromatography using gradient elution
and either a Zorbax Eclipse XDB-C18 column (Agilent Tech-
nologies; for FTC, TFV, and ZDV) or an Acquity UPLC BEH
C18 column (Waters; for all other drugs). Eluted analytes were
subjected to positive electrospray ionization with detection in
multiple reaction-monitoring mode. The lower limit of detec-
tion was <5 ng/mL for FTC, TFV, and ZDV, 20 ng/mL for 3TC,
d4T, and NVP, and 100 ng/mL for the remaining drugs. Results
were reported as positive or negative for each analyte.
Statistical Analysis
We used χ2 and Fisher’s exact tests to compare differences in
proportions of categorical variables and the Wilcoxon rank sum
test to compare differences in medians for continuous variables
between individuals in the virally suppressed group with or
without ARV drugs detected. Virologic failure was defined as 2
consecutive viral load measurements >1000 copies/mL ≥16
weeks after ART initiation. Analyses were performed using SAS
software, version 9.2.
Ethical Considerations
Written informed consent was obtained from all participants in
the HPTN 052 trial. The trial was approved by institutional review
boards or ethics committees at each participating institution.
RESULTS
Detection of ARV Drugs in Enrollment Samples
Enrollment samples from 209 HIV-infected index participants
were tested for ARV drugs (Supplementary Figure 1). None of
the women in this substudy reported receiving ARV drugs for
pMTCT within the month before enrollment. Forty-eight par-
ticipants (23.0%) had ≥1 ARV drug(s) detected: 45 of 96
(46.9%) in the virally suppressed group, 2 of 48 ( 4.2%) in the
low viral load group, and 1 of 65 (1.5%) in the high viral load
group (P < .0001). The following drugs were detected in the
virally suppressed group: NVP + 3TC + d4T (n = 21), NVP + 3TC
(n = 14), NVP alone (n = 4), NVP + ZDV + 3TC (n = 2),
NVP + d4T (n = 2), NVP + ZDV+ d4T (n = 1), and ZDV + d4T
(n = 1). The drugs detected in the low viral load group were
NVP + 3TC (n = 1) and ZDV alone (n = 1). Only 1 (1.5%) of
the 65 samples from the high viral load group had an ARV
drug detected (3TC only).
The 48 participants who had ARV drugs detected (including
45 in the virally suppressed group; Tables 1 and 2), were en-
rolled at 6 study sites in 5 countries; 22 were randomized to the
early ART arm, and 26 to the delayed ART arm. None of these
48 participants transmitted HIV to his or her partner, and only
2 of 161 participants who did not have ARV drugs detected at
enrollment transmitted HIV to their partners.
Factors Associated With Detection of ARV Drugs at Enrollment
We examined the association of demographic and clinical
factors with detection of ARV drugs at enrollment among the
96 participants in the virally suppressed group. In this group,
ARV drugs were detected in 41 of 73 samples (56.2%) from
Africa, 4 of 12 (33.3%) samples from Asia, and none of 11
samples from the Americas (P = .001). ARV drug detection by
country is shown in Table 1. CD4 cell count at enrollment was
lower among participants who had ARV drugs detected than
among those who did not have (median, 403 vs 472 cells/mm3;
P < .001). There was no significant association of ARV drug de-
tection with age, sex, report of previous ARV use for pMTCT,
or self-reported condom use (Table 2). Among 51 participants
in the immediate ART study arm, there was no significant diffe-
rence in frequency of virologic failure during the first year of
study-administered ART between those who did and those who
did not have ARV drugs detected at enrollment (1 of 19 [5.3%]
vs none of 32, respectively; P = .37). Viral load data from
follow-up visits is presented in Supplementary Figure 2.
Detection of ARV Drugs in Follow-up Samples
We next examined whether participants who had ARV drugs
detected at enrollment continued to use ARV drugs off study
after enrollment. This analysis was limited to the 16 partici-
pants in the virally suppressed group who were randomized to
the delayed ART arm and had ≥1 follow-up visit with a viral
load <1000 copies/mL before initiation of study-administered
ART. At least 1 ARV drug was detected in 46 of 47 samples
tested (median, 3 samples per participant); the drugs detected
were NVP + 3TC + d4T (n = 35), NVP + 3TC (n = 8), NVP +
ZDV + 3TC (n = 2), and NVP alone (n = 1). In 12 participants,
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the drugs detected in the follow-up samples were also detected in
the corresponding enrollment sample; in 4 participants, d4T was
detected in follow-up samples but not at the enrollment visit.
DISCUSSION
This study examined off-study ARV drug use in HIV-infected
index participants in HPTN 052. All index participants en-
rolled in the trial denied prior or current ART at the time of
study enrollment. Off-study ARV use was documented in ap-
proximately half of the participants with viral suppression
(overall, 45 of 96 [46.9%]; in Africa, 41 of 73 [56.2%). This
group represented 2.8% of the 1582 enrolled index participants
for whom viral load data were available from the enrollment
visit. ARV drugs were also detected in a small number of par-
ticipants with higher viral loads (2 of 48 participants [4.2%]
with viral loads 401–1000 copies/mL; 1 of 65 randomly selected
participants [1.5%] with viral loads >1000 copies/mL). In the
virally suppressed group, detection of ARV drugs at enrollment
was associated with a lower baseline CD4 cell count.
Off-study ARV use at enrollment did not seem to affect the
response to study-administered ART. Among participants who
were randomized to the early ART arm of the trial, detection of
ARV drugs at enrollment was not associated with a lack of viral
suppression or treatment failure during the first year of study-
administered ART. Among participants in the delayed ART
arm of the trial, viral suppression during the first year of the
trial in the absence of study-administered ART was more
common among participants who had ARV drugs detected at
enrollment. In many cases, those participants continued to use
off-study ARV drugs after enrollment, which was not disclosed
to study staff.
The findings of this study and the report from the Partners
in Prevention HSV/HIV Transmission trial [2] highlight the
limitations of using self-report to gather information about past
or current ARV drug use. There are many reasons why partici-
pants may have chosen not to disclose ARV drug use at enroll-
ment in HPTN 052. Disclosure of past or current ART would
have excluded them from enrollment and the trial’s potential
benefits (eg, perceived opportunity for improved routine care,
access to study-administered ART, possible prevention benefits
for partners, and reimbursement for travel). Furthermore,
some HIV-infected individuals may have not disclosed their
HIV status to their partner before enrollment (fearing stigma,
discrimination, or partner abandonment); they may have pre-
ferred to disclose their HIV status to their partner at enrollment
Table 1. Detection of ARV Drugs at Study Enrollment by Country and Region Among Index Participants With a Viral Load ≤400 Copies/mL
at Study Enrollment











77 (4.4) 60 (3.4) 481 (27.3) 96 (5.5) 240 (13.6) 425 (24.1) 106 (6) 276 (15.7) 2 (0.1) 1763
Enrolled in
this studya
77 (100) 60 (100) 481 (100) 96 (100) 240 (100) 250 (58.8) 106 (100) 276 (100) 2 (100) 1588
Viral load data
availableb
76 (4.8) 60 (3.8) 476 (30.1) 96 (6.1) 240 (15.2) 250 (15.8) 106 (6.7) 276 (17.5) 2 (0.1) 1582
Virally
suppressedc
5 (5.2) 1 (1) 34 (35.4) 11 (11.5) 22 (22.9) 11 (11.5) 1 (1) 11 (11.5) 0 96
ARV drug(s)
detected









0/76 1/60 (1.7) 20/476 (4.2) 1/96 (1.0) 19/240 (7.9) 4/250 (1.6) 0/106 0/276 0/2 45/1582
(2.8)
Abbreviation: ARV, antiretroviral.
a A total of 1763 couples were enrolled in HPTN 052. This substudy included 12 of the 13 HPTN 052 study sites (see Methods).
b Six index participants (1 from Botswana, 5 fromMalawi) did not have viral load data from the enrollment visit.
c Virally suppressed was defined as a viral load ≤400 copies/mL at the enrollment visit.
d For these data, the denominator (number tested) indicates the number of samples with viral load data available from the region indicated in the column header.
e For these data, the denominator (number tested) indicates the number of samples tested for the presence of ARV drugs from the region indicated in the column
header.
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with the help of a trained couples counselor and may therefore
have chosen not to disclose past or current ART.
It is important to note that undisclosed ART use in HPTN
052 could have reduced the apparent impact of the study inter-
vention: early ART for prevention of HIV transmission. This is
because participants in the delayed ART arm (control study
arm) who were virally suppressed from off-study ART would
have been less likely to transmit HIV to their partners. There-
fore, it is notable that the remarkable effect of the study inter-
vention (a 96% reduction in HIV transmission with early ART)
was apparent, even though some study participants were taking
ART outside of the study [3].
The frequency of undisclosed off-study ARV drug use
among HIV-infected participants with undetectable viral loads
at enrollment was similar in HPTN 052 and the Partners in
Prevention HSV/HIV Transmission study [2] (46.9% and
46.0%, respectively). In HPTN 052, off-study ARV drug use
was most common at the African study sites and was also ob-
served in Asia but not in the Americas. The HIV-infected indi-
viduals with undetectable viral loads and no evidence of ARV
drug use may have been elite controllers. In HPTN 052, these
individuals accounted for 51 (3.2%) of the 1582 participants in-
cluded in this substudy. This indicates that the presence of an
undetectable viral load in the absence of study-administered
ART does not necessarily indicate off-study ARV drug use.
Further studies are needed to evaluate the potential impact of
enrolling elite controllers in different clinical trial settings.
It is important to emphasize that ARV drug screening was
performed only in a subset of participants in HPTN 052; only
209 (11.9%) of the 1763 index participants in HPTN 052 were
tested. The finding of off-study ARV use in some participants
emphasizes the potential value of ARV testing in a many differ-
ent types of clinical trials. Further studies are needed to deter-
mine the frequency of undisclosed ARV use in different clinical
and research settings and to understand the reasons that a study
participant may chose not to disclose use of ARV drugs. Evalu-
ation of off-study ARV use may also be important in studies
that enroll HIV-uninfected individuals, because ARV drugs are
also used for preexposure prophylaxis [4–7] and may be used
as recreational drugs [7–10]. ARV drug testing may also be im-
portant for studies of elite controllers, because some individuals
receiving ART may not disclose their HIV infection status.
Recent development of a low-cost, high-throughputARVscreen-
ing assay [11] may facilitate this type of analysis in future studies.
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